Brain Metastases Clinical Trials

42 studies are recruiting for brain metastases in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. MeDex: No Perioperative Dexamethasone in Brain Metastases

   Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Louisville Hospital, Louisville, Kentucky

   Run by

   University of Louisville

   See if you can join NCT07044557 on ClinicalTrials.gov

2. 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

   This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis aft…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Miami Cancer Institute, Miami, Florida

   Run by

   Baptist Health South Florida

   See if you can join NCT06048094 on ClinicalTrials.gov

3. Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

   This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06712927 on ClinicalTrials.gov

4. Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

   The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In additi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Miami Cancer Institute, Miami, Florida

   Run by

   Baptist Health South Florida

   See if you can join NCT04689048 on ClinicalTrials.gov

5. Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

   Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT07462507 on ClinicalTrials.gov

6. NTS-WBRT in Brain Metastases

   This research is being done to assess the quality of life and symptom burden in participants who receive (normal tissue sparing whole brain radiation therapy (NTS-WBRT). This research study involves: * NTS-WBRT (normal tissue sparing whole brain radiation therapy) * Memantine standard of care drug

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05013892 on ClinicalTrials.gov

7. Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

   This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford University, Stanford, California

   Locations

   3 in total

   Run by

   Joshua Palmer

   See if you can join NCT05987644 on ClinicalTrials.gov

8. Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

   Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg…

   Stage

   Phase 1

   Ages

   19 to 90

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   3 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT03449238 on ClinicalTrials.gov

9. Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

   The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation thera…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05559853 on ClinicalTrials.gov

10. Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

    This study investigates fluorine-18-AlphaVBeta6-BP ([18F]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that [18F]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of California Davis Comprehensive Cancer Center, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT05452005 on ClinicalTrials.gov

11. Evaluation of the CONVIVO System

    The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventio…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

    Run by

    Dartmouth-Hitchcock Medical Center

    See if you can join NCT05139277 on ClinicalTrials.gov

12. Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

    To learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05700721 on ClinicalTrials.gov

13. Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

    The goal of this interventional clinical trial is to provide proof-of-principle data for the biologic activity of defactinib in combination with avutometinib in brain metastases from melanoma, and to define the potential role of the combination with mutant BRAF inhibitors or after BRAF/MEK inhibito…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Iowa, Iowa City, Iowa

    Locations

    2 in total

    Run by

    University of Utah

    See if you can join NCT06194929 on ClinicalTrials.gov

14. 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

    Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Missouri, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT07175077 on ClinicalTrials.gov

15. Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

    This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Miami Cancer Institute at Baptist Health South Florida, Miami, Florida

    Run by

    Baptist Health South Florida

    See if you can join NCT05554302 on ClinicalTrials.gov

16. Stereotactic Magnetic Resonance Guided Radiation Therapy

    This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Ph…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04115254 on ClinicalTrials.gov

17. Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

    This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

    Run by

    Vanderbilt-Ingram Cancer Center

    See if you can join NCT05996432 on ClinicalTrials.gov